La Crosse encephalitis
This article needs additional citations for verification. (September 2015) (Learn how and when to remove this template message)
|La Crosse encephalitis|
La Crosse encephalitis virus (LACV) is one of a group of mosquito-transmitted viruses that can cause encephalitis, or inflammation of the brain. LAC encephalitis is rare; in the United States, about 80–100 LACV disease cases are reported each year, although it is believed to be under-reported due to minimal symptoms experienced by many of those affected.
Signs and symptoms
It takes 5 to 15 days after the bite of an infected mosquito to develop symptoms of LACV disease. Symptoms include nausea, headache, vomiting in milder cases and seizures, coma, paralysis and permanent brain damage in severe cases.
LAC encephalitis initially presents as a nonspecific summertime illness with fever, headache, nausea, vomiting and lethargy. Severe disease occurs most commonly in children under the age of 16 and is characterized by seizures, coma, paralysis, and a variety of neurological sequelae after recovery. Death from LAC encephalitis occurs in less than 1% of clinical cases. In many clinical settings, pediatric cases presenting with CNS involvement are routinely screened for herpes or enteroviral causes. Since there is no specific treatment for LAC encephalitis, physicians often do not request the tests required to specifically identify LAC virus, and the cases are reported as aseptic meningitis or viral encephalitis of unknown cause.
|La Crosse Virus|
Group V ((−)ssRNA)
La Crosse Virus
Most cases of LAC encephalitis occur in children under 16 years of age. LAC virus is a zoonotic pathogen cycled between the daytime-biting treehole mosquito, Aedes triseriatus, and vertebrate amplifier hosts (chipmunks, tree squirrels) in deciduous forest habitats. The virus is maintained over the winter by transovarial transmission in mosquito eggs. If the female mosquito is infected, she may lay eggs that carry the virus, and the adults coming from those eggs may be able to transmit the virus to chipmunks and to humans.
Anyone bitten by a mosquito in an area where the virus is circulating can get infected with LACV. The risk is highest for people who live, work or recreate in woodland habitats, because of greater exposure to potentially infected mosquitoes.
People reduce the chance of getting infected with LACV by preventing mosquito bites. There is no vaccine or preventive drug.
Prevention measures against LACV include reducing exposure to mosquito bites. Use repellent such as DEET and picaridin, while spending time outside, especially at during the daytime - from dawn until dusk. Aedes triseriatus mosquitoes that transmit (LACV) are most active during the day. Wear long sleeves, pants and socks while outdoors. Ensure all screens are in good condition to prevent mosquitoes from entering your home. Aedes triseriatus prefer treeholes to lay eggs in. Also, remove stagnant water such as old tires, birdbaths, flower pots, and barrels.
No specific therapy is available at present for La Crosse encephalitis, and management is limited to alleviating the symptoms and balancing fluids and electrolyte levels. Intravenous ribavirin is effective against La Crosse encephalitis virus in the laboratory, and several studies in patients with severe, brain biopsy confirmed, La Crosse encephalitis are ongoing.
In a trial with 15 children being infected with La Crosse viral encephalitis were treated at certain phases with ribavirin (RBV). RBV appeared to be safe at moderate doses. At escalated doses of RBV, adverse events occurred and then the trial was discontinued. Nonetheless, this was the largest study of antiviral treatment for La Crosse encephalitis.
La Crosse encephalitis was discovered in 1965, after the virus was isolated from stored brain and spinal tissue of a child who died of an unknown infection in La Crosse, Wisconsin in 1960. It occurs in the Appalachian and Midwestern regions of the United States. Recently there has been an increase of cases in the South East of the United States. An explanation to this may be that the mosquito Aedes albopictus is also an efficient vector of La Crosse virus. Aedes albopictus is a species that has entered the US and spread across the SE of the US and replaced Aedes aegypti in most areas (which is not an efficient vector of LAC).
Historically, most cases of LAC encephalitis occur in the upper Midwestern states (Minnesota, Wisconsin, Iowa, Illinois, Indiana, and Ohio). Recently, more cases are being reported from states in the mid-Atlantic (West Virginia, Virginia and North Carolina) and southeastern (Alabama and Mississippi) regions of the country. It has long been suspected that LAC encephalitis has a broader distribution and a higher incidence in the eastern United States, but is under-reported because the causal agent is often not specifically identified.
LAC encephalitis cases occur primarily from late spring through early fall, but in subtropical areas where the mosquito is found (e.g., the Gulf states), rare cases can occur in winter.
According to the CDC, between 2004 and 2013 there were 787 total cases of La Crosse encephalitis and 11 deaths in the U.S.
Looking at the distribution of cases across the United States by state, between 2004 and 2013 the most cases of La Crosse encephalitis was in North Carolina. North Carolina had 184 total cases, followed by Ohio with 178 total cases.
- McJunkin, J. E.; de los Reyes, E. C.; Irazuzta, J. E.; Caceres, M. J.; Khan, R. R.; Minnich, L. L.; Fu, K. D.; Lovett, G. D.; Tsai, T.; Thompson, A. (March 2001). "La Crosse Encephalitis in Children". The New England Journal of Medicine. 344 (11): 801–7. doi:10.1056/NEJM200103153441103. PMID 11248155.CS1 maint: Multiple names: authors list (link)
- "Epidemiology & Geographic Distribution | la Crosse encephalitis | CDC". 2018-09-14.
- Center for Disease Control and Prevention (CDC) (January 2009). "Possible Congenital Infection with La Crosse Encephalitis Virus — West Virginia, 2006–2007". MMWR. Morbidity and Mortality Weekly Report. 58 (1): 4–7. PMID 19145220.
- "Prevention". Centers for Disease Control and Prevention. 11 April 2016. Retrieved 6 December 2016.
- McJunkin, JE (October 2011). "Safety and pharmacokinetics of ribavirin for the treatment of la crosse encephalitis". The Pediatric Infectious Disease Journal. 30 (10): 860–5. doi:10.1097/INF.0b013e31821c922c. PMID 21544005.
- Thompson, W.H.; Kalfayan, B.; Anslow, R.O. (1965). "Isolation of California encephalitis virus from a fatal human illness". Am. J. Epidemiol. 81 (2): 245–253. doi:10.1093/oxfordjournals.aje.a120512. PMID 14261030.CS1 maint: Multiple names: authors list (link)
- "La Crosse virus disease cases and deaths reported to CDC by year and clinical presentation, 2004-2013" (PDF). Centers for Disease Control and Prevention. Retrieved 4 December 2016.
- "La Crosse virus disease cases reported to CDC by state, 2004–2013" (PDF). Centers for Disease Control and Prevention. Retrieved 8 December 2016.
- "La Crosse Encephalitis". CDC. 2018-05-03. Retrieved 2012-02-25.
- Directors of Health Promotion and Education Facts Sheet La Crosse Encephalitis
- Encephalitis Global Inc. Offering information and support to encephalitis survivors, caregivers and loved ones.